Substance and claimed effects

Restless legs syndrome (RLS), also called Willis-Ekbom disease, is a sensorimotor disorder defined by an urge to move the legs, usually accompanied by uncomfortable sensations, that begins or worsens at rest, is partially or completely relieved by movement, and worsens in the evening or at night — a phenotype not better explained by another condition Allen et al. 2014. Roughly 5–10% of European-descent adults have RLS by IRLSSG criteria; 1.5–3% have clinically significant disease that disrupts sleep, and prevalence rises with age and is roughly twice as high in women Ohayon et al. 2012. The dossier covers the substance and the consequences flagged in the brief — sleep onset, sleep maintenance, daytime fatigue, mood — plus mechanism (central nervous system iron handling, dopaminergic signalling), the diagnostic role of ferritin assessment, and the therapeutic role of iron repletion (oral and IV), with a short note on pharmacotherapy where iron is insufficient.

Evidence by addressing question

mechanism

RLS is fundamentally a disorder of central iron handling rather than peripheral iron deficiency. Post-mortem examination of RLS brains shows reduced iron and reduced H- and L-ferritin in the substantia nigra and putamen, with diminished transferrin receptor expression — a pattern consistent with impaired iron uptake into dopaminergic neurons rather than simple body-iron shortage Connor et al. 2003. CSF ferritin is reduced even when serum ferritin is normal, and MRI iron measures (R2*, susceptibility-weighted imaging) confirm regional brain iron deficits Trenkwalder et al. 2018. Iron is a cofactor for tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis; the resulting dopaminergic dysregulation (presynaptic upregulation, postsynaptic D2-receptor downregulation, evening trough in striatal dopamine) explains the circadian pattern and the paradoxical response to dopamine agonists over time Trenkwalder et al. 2018. Glutamate and adenosine signalling also appear involved, which is the proposed mechanism for the efficacy of alpha-2-delta calcium-channel ligands (gabapentin enacarbil, pregabalin) Winkelman et al. 2025. Heritability is substantial: GWAS identifies common variants near MEIS1, BTBD9, MAP2K5/SKOR1, and PTPRD with odds ratios up to ~1.8 — among the largest known for any complex disease Stefansson et al. 2007 Winkelmann et al. 2017.

evidence

RLS is a clinical diagnosis, not a lab diagnosis. The IRLSSG 2014 revision requires all five core criteria plus exclusion of mimics such as nocturnal leg cramps, positional discomfort, habitual foot-tapping, vascular or neurogenic claudication, and arthralgias Allen et al. 2014. Ferritin is the most useful single lab; transferrin saturation, CBC, and renal function add context. The IRLSSG 2018 consensus operationalises the iron threshold: oral iron is recommended when serum ferritin is <75 ng/mL with transferrin saturation <45%, and IV iron is recommended when serum ferritin is <100 ng/mL (or <300 with sat <45%) Allen et al. 2018. The threshold is set above the conventional anaemia cutoff (~15–30 ng/mL) precisely because peripheral stores must be substantially full before brain iron rises — RLS patients are not iron-deficient by haematology standards, yet still respond to repletion. The 2025 AASM clinical practice guideline endorses ferritin-guided iron repletion and gives a STRONG recommendation for IV ferric carboxymaltose in adults with RLS and ferritin ≤300 ng/mL with transferrin saturation <45% Winkelman et al. 2025.

For treatment efficacy: a multicentre placebo-controlled trial of a single 1000-mg IV ferric carboxymaltose infusion produced large, durable improvements in IRLS severity scores out to several weeks Allen et al. 2011. Oral ferrous sulfate (or polysaccharide-iron complex) shows benefit in low-ferritin patients but with a slower onset (weeks to months) and higher GI burden. The 2025 AASM guideline downgraded dopamine agonists (pramipexole, ropinirole, rotigotine) from first-line to conditional-against in chronic adult RLS — the decisive consideration being augmentation, the long-term paradoxical worsening of symptoms — and promoted alpha-2-delta ligands (gabapentin enacarbil with the strongest evidence base, plus pregabalin and gabapentin) to first-line pharmacotherapy Winkelman et al. 2025.

protocol

The action sequence the dossier supports: (1) confirm the diagnosis against the five IRLSSG criteria Allen et al. 2014; (2) order serum ferritin and transferrin saturation as the first lab pass — these are the only labs that change first-line management Allen et al. 2018; (3) remove aggravators (see contraindications and failure-modes); (4) if ferritin <75 ng/mL, start oral iron (typically ferrous sulfate 325 mg, or equivalent elemental iron 65 mg) taken every other day on an empty stomach with vitamin C — every-other-day dosing increases fractional absorption by lowering hepcidin response and reduces GI side effects Allen et al. 2018; (5) recheck ferritin at 8–12 weeks; aim for ferritin >100 ng/mL with saturation >20% (and ideally >25–35%); (6) if oral iron fails (no response after 3 months, GI intolerance, persistent ferritin <100) or symptoms are severe enough to warrant rapid relief, refer for IV ferric carboxymaltose (typically 750–1000 mg, single or split dose) — now a STRONG AASM recommendation Winkelman et al. 2025; (7) if iron alone is inadequate after ferritin is repleted, add an alpha-2-delta ligand (gabapentin enacarbil 600 mg evening, or gabapentin/pregabalin equivalents) before considering dopamine agonists, because of augmentation risk Winkelman et al. 2025.

contraindications

The dominant safety concern in this entry is the iron-repletion arm of the protocol, not the diagnosis itself. Iron repletion is contraindicated in hereditary haemochromatosis and in iron-overload states, including transfusion-dependent anaemias; ferritin and transferrin saturation are the screening pair that catches these before supplementation Allen et al. 2018. IV ferric carboxymaltose can cause hypophosphataemia (sometimes symptomatic) and rare hypersensitivity reactions; current FDA labelling requires infusion in a setting equipped for resuscitation Winkelman et al. 2025. For pharmacotherapy: dopamine agonists carry the augmentation hazard (with 5-year cumulative incidence on the order of 40–70%) Garcia-Borreguero et al. 2016; alpha-2-delta ligands carry sedation, dizziness, weight gain, and pose abuse risk in patients with substance-use histories Winkelman et al. 2025. In pregnancy, RLS is common (incidence ~20% by the third trimester) and largely transient; most pharmacotherapy is contraindicated, and oral iron (with ferritin guidance) is the mainstay Picchietti et al. 2015.

misconceptions

Five durable wrong beliefs surfaced in this dossier. First, "normal" ferritin (the lab reference range typically starting at 15–30 ng/mL) is the wrong threshold for RLS — the operational cutoff for oral iron is <75 ng/mL and for IV iron <100 ng/mL, so most patients told their iron is "fine" by haematology criteria are not, for the purposes of this disease Allen et al. 2018. Second, RLS is not a peripheral muscle or vascular problem — it is a CNS disorder with no leg pathology on exam, which is why pulses, ankle-brachial index, and electromyography are typically normal Trenkwalder et al. 2018. Third, "growing pains" in children and "nervous habits" in adults frequently mask paediatric or early-adult RLS, which is highly heritable and runs in families Winkelmann et al. 2017. Fourth, dopamine agonists were standard first-line therapy for ~two decades and are still widely prescribed — but the 2025 AASM guideline now recommends against routine first-line use in adults due to augmentation Winkelman et al. 2025. Fifth, many widely used medications cause or unmask RLS — particularly serotonergic antidepressants (SSRIs, SNRIs, mirtazapine), first-generation antihistamines (diphenhydramine in "PM" sleep aids), dopamine-blocking antiemetics (metoclopramide, prochlorperazine), and antipsychotics; many sufferers are unknowingly on an aggravator Trenkwalder et al. 2018.

audience

Women are affected roughly twice as often as men in adulthood; the gap opens after the first pregnancy and is not fully closed by parity adjustments Ohayon et al. 2012. Pregnancy itself triples risk during the third trimester, with most cases remitting postpartum; the management approach (ferritin assessment, oral iron) holds and most pharmacotherapy is avoided Picchietti et al. 2015. Prevalence rises with age across the adult lifespan and peaks in the 60s–70s. Two clinical subpopulations have notably higher prevalence and faster progression: end-stage renal disease patients on dialysis (prevalence 20–30%), and patients with iron deficiency anaemia for any reason Trenkwalder et al. 2018. Family history is positive in roughly 50–60% of early-onset (under 45) cases, suggesting a strongly genetic subtype that responds particularly well to iron repletion Winkelmann et al. 2017.

alternatives

Non-pharmacological measures supported by the literature include moderate exercise (regular but not intense in the evening), pneumatic compression devices, near-infrared light, vibratory pads, and mental-engagement strategies; effect sizes are modest individually but additive and free of side effects Winkelman et al. 2025. Caffeine, nicotine, and alcohol reduction help a subset. When iron is repleted and behavioural measures are insufficient, alpha-2-delta ligands are the preferred pharmacotherapy; opioids (low-dose methadone, oxycodone) are reserved for severe refractory disease under specialist care Winkelman et al. 2025.

failure-modes

The single most common reason "I tried iron and it didn't work": insufficient dose, insufficient duration, or insufficient absorption. Oral iron is poorly absorbed (~2–13% bioavailability); daily dosing actually reduces absorption versus every-other-day dosing because of the hepcidin feedback loop, and 3 months is typically needed to see ferritin rise meaningfully Allen et al. 2018. The second mode: GI side effects (constipation, nausea, dark stool) cause non-adherence; switching to lower elemental iron doses, every-other-day dosing, or liquid forms helps, and IV iron bypasses the GI tract entirely. The third mode: undiscovered medication aggravation — patients on SSRIs or nightly diphenhydramine often improve substantially just by changing the offending drug class. The fourth: dopamine-agonist augmentation — patients on pramipexole or ropinirole for years whose symptoms gradually worsen, start earlier in the day, and spread to the arms are experiencing augmentation, not disease progression; the management is taper and switch, not dose escalation Garcia-Borreguero et al. 2016.

stakes

Untreated RLS damages sleep onset (long latency to sleep, hours in bed not asleep), sleep maintenance (frequent awakenings, often linked to periodic limb movements of sleep), and total sleep time. Polysomnography shows sleep efficiency reductions of 15–30% in moderate-severe RLS and a measurable drop in slow-wave sleep Trenkwalder et al. 2018. The downstream consequences are the standard sleep-debt cascade — daytime fatigue, irritability, attention lapses, impaired vigilance — compounded by the bidirectional link with mood disorders: prevalence of major depression in RLS is roughly 2–3× the general population, and several antidepressants used to treat that depression aggravate the RLS Hornyak 2010. Observational cohorts have linked severe RLS to elevated cardiovascular risk and, in one large male cohort, increased all-cause mortality, although confounding by sleep deprivation and comorbidity makes the causal arrow uncertain Li et al. 2013.

payoff

The honest curve: with adequate iron repletion in iron-deficient RLS (the bulk of cases), the IRLS severity score typically drops by 8–10 points and sleep latency, awakenings, and self-rated sleep quality improve within 2–8 weeks for IV iron and 2–4 months for oral iron Allen et al. 2011 Allen et al. 2018. Daytime fatigue and mood typically improve in parallel with sleep, reflecting recovered sleep architecture rather than a direct effect on those systems. A subset has durable remission for years on a single IV iron course; others need re-dosing every 6–24 months when ferritin drifts back below threshold Allen et al. 2018. Patients with augmentation who are tapered off dopamine agonists onto an alpha-2-delta ligand and given iron repletion frequently describe the change as "getting their evenings back" — the felt experience is more about reclaiming the hours from 8 PM to bedtime than about any single symptom score.

practicalities

Ferritin and transferrin saturation are inexpensive labs typically covered by insurance and orderable by primary care, sleep medicine, or neurology. Oral iron is over-the-counter, ~$5–30 per month. IV ferric carboxymaltose is a single or split-dose infusion (~30 minutes), with cost in the US typically ranging from $1,000–3,000 per dose depending on payer; coverage for RLS varies, and some patients pay out of pocket. Alpha-2-delta ligands are generic and inexpensive. Sleep medicine specialists and movement-disorder neurologists are the right escalation referral when oral iron and aggravator removal don't suffice.

history

The clinical syndrome was described by Sir Thomas Willis in 1672 and named by Ekbom in 1945; the IRLSSG diagnostic criteria were formalised in 1995 and updated in 2003 and 2014 Allen et al. 2014. The brain-iron hypothesis was sharpened by Connor and colleagues in the early 2000s Connor et al. 2003; the first GWAS hits arrived in 2007 Stefansson et al. 2007. The pharmacological history is a cautionary arc: dopamine agonists were embraced as first-line in the 2000s on the strength of short-term trials, augmentation emerged as a chronic-treatment problem in the 2010s, and the 2025 AASM guideline reversed first-line status to alpha-2-delta ligands and IV iron Winkelman et al. 2025.

out-of-scope

Periodic limb movements of sleep (PLMS) overlap with but are not identical to RLS — about 80–90% of RLS patients have PLMS, but PLMS occurs in many sleep disorders and ageing without RLS. Iron deficiency anaemia, ferritin testing in non-RLS contexts, and the broader sleep-debt cascade are adjacent and deserve their own treatment. Restless-legs-like sensations in peripheral neuropathy, akathisia (a drug-induced movement disorder that can mimic RLS), and small-fibre neuropathy belong to different entries.

The credibility range

Optimist case

RLS is one of the cleanest mechanism-to-treatment stories in sleep medicine: a CNS iron-handling disorder for which a cheap, ubiquitous diagnostic lab (ferritin) maps directly to a cheap, mostly safe, often dramatically effective treatment (iron repletion). Well-defined diagnostic criteria Allen et al. 2014, randomised-trial backing for IV iron Allen et al. 2011, multiple converging guidelines from IRLSSG, EURLSSG, and AASM Allen et al. 2018 Winkelman et al. 2025, and large GWAS signals confirming biological reality Stefansson et al. 2007. The historical mistake (dopamine agonists first-line, augmentation later) has been corrected by guideline revision. The reader-relevant punchline holds: the symptom pattern is identifiable, the test is one tube of blood, and the first-line treatment is iron — not a drug, not a controlled substance, not a life sentence.

Skeptic case

RLS overlaps phenotypically with several common, non-pathological experiences (positional leg discomfort, occasional restlessness, habitual movement) and the IRLSSG criteria can be misapplied — community-level prevalence estimates of 5–10% drop to 1.5–3% when clinically significant disease is required Ohayon et al. 2012. Oral iron trials in RLS are smaller and less consistent than the IV iron literature, and the ferritin threshold (75/100 ng/mL) is a consensus call, not a number derived from a single defining RCT Allen et al. 2018. The CV-mortality association rests on observational cohorts and is confounded by sleep deprivation, antidepressant use, and comorbid renal/cardiac disease Li et al. 2013. Some patients labeled with RLS have akathisia, neuropathy, or psychiatric restlessness instead; the diagnostic specificity of the criteria depends on rigorous exclusion of mimics.

Author's call

The entry lands close to the optimist position: diagnostic criteria are clear, mechanism is well-mapped, iron is a high-yield first move that costs almost nothing, and the recent AASM guideline shift to iron-first/gabapentinoid-second is the right correction of an earlier mistake. The skeptic considerations narrow the population (not every leg-twitch is RLS) but do not undermine the recommendation pathway for confirmed cases. Evidence rates a 4; controversy rates a 2, mostly because the dopamine-agonist legacy still pervades older clinical practice and some endpoints (mortality, exact ferritin cutoff) remain contested at the margins.

Stakeholder + incentive map

The dopamine-agonist sales arc shaped clinical practice through the 2000s–2010s and explains residual prescribing inertia in primary care; manufacturer-sponsored short-term trials understated augmentation, which only surfaced in longer follow-up. IV iron makers (ferric carboxymaltose, ferumoxytol, low-molecular-weight iron dextran) now have a financial interest in expanded RLS indications. The IRLSSG and EURLSSG are specialist societies aligned with the iron-first model and have funded the consensus statements. Sleep-foundation advocacy groups push for ferritin awareness because under-testing is a real bottleneck. The skeptic counter-incentive is mostly inertia (primary-care unfamiliarity with the 75/100 ng/mL threshold) and the cost of IV iron in fee-for-service systems.

Population variability

Three subgroups respond especially well to iron-first management: pregnant women (transient, iron-driven, oral iron sufficient in most), early-onset/familial RLS (strong genetic loading, classic iron-responsive phenotype), and dialysis patients (often profoundly iron-deficient). Older adults with multifactorial sleep disruption respond more modestly because their RLS is layered with other sleep pathology. Patients already on long-term dopamine agonists experiencing augmentation respond best to a structured taper plus an alpha-2-delta switch plus iron repletion — not to dose escalation. Men and women have similar mechanistic profile but women are more often underdiagnosed because symptoms are misattributed to "anxiety" or "leg cramps."

Knowledge gaps

The most consequential open questions: the exact optimal ferritin target (most data support >100 ng/mL, but whether >150 or >200 produces additional benefit is unsettled); the long-term safety of repeated IV iron courses across decades; whether gabapentin enacarbil's effect is durable in trials longer than 1–2 years; whether non-iron-deficient RLS (ferritin already >100) is a separate biological subtype or simply a treatment-resistant phenotype; and whether early iron repletion in childhood RLS modifies adult disease trajectory Winkelman et al. 2025. The CV/mortality association remains causally ambiguous, and well-powered RCTs of treating RLS to lower CV endpoints are not feasible. Hypophosphataemia after repeated ferric carboxymaltose courses is increasingly recognised but not yet quantified for the RLS population specifically.

Scope vs. brief. The brief named sleep onset, sleep maintenance, daytime fatigue, mood, and the diagnostic/therapeutic role of ferritin and iron repletion. All five are covered end to end: sleep onset and maintenance run through mechanism, stakes, and payoff; daytime fatigue and mood are explicit in stakes and payoff; ferritin and iron occupy evidence, protocol, and failure-modes. No narrowing.

Action verb. Chose respond over test. The reader's job is not just "go get a ferritin test" — the test is one step inside a sequence (recognise pattern → test → pull aggravators → iron course → recheck → escalate). respond captures the symptom-triggered protocol shape better than test alone.

Rating difficulties. longevity was the hardest call. Severe RLS shows associations with cardiovascular events and all-cause mortality in observational cohorts (Li et al. 2013) but causality is tangled with sleep deprivation and comorbidity. Scored 1 (marginal contribution) rather than 0 to honour the signal, but not 2, because a confident "small additive mortality effect" overstates the evidence. mood was scored 3 rather than 2 on the strength of the 2–3× depression comorbidity (Hornyak 2010) and the bidirectional pharmacology link with SSRIs; the effect is real and treatable, not a side note.

The dopamine-agonist guideline reversal. The 2025 AASM guideline (Winkelman et al. 2025) is recent and a meaningful break from the 2000s–2010s standard of care. The article surfaces it in two places (misconceptions and protocol) rather than spinning it off into a standalone history section, because the practical reader-relevant point is "your old prescription may now be wrong," not "here is the regulatory arc."

No standalone alternatives or history. Alpha-2-delta ligands and IV iron are presented inside protocol because they are part of the sequence, not parallel paths. The historical Willis-1672 / Ekbom-1945 arc was considered for a history section but adds no actionable information; the field's pharmacological history is mentioned briefly in the dopamine-agonist context where it matters.

Audience scoping. Did not set audience.gender in meta because RLS itself isn't gender-locked, even though prevalence is doubled in women. Pregnancy is handled as a sub-audience block inside the audience addressing section rather than scoping the whole entry.

Contraindications. Only hemochromatosis is set — the bright safety line for iron repletion. Pregnancy is discussed in prose because pregnancy doesn't contraindicate the entry (oral iron is exactly the right treatment in pregnancy), it just changes the protocol.

Separate-entry candidates.

• Periodic limb movements of sleep — overlaps with RLS but is mechanistically and clinically distinct.
• Dopamine-agonist augmentation — substantial enough as a clinical entity to deserve its own treatment, especially for the population still on pramipexole / ropinirole.
• IV iron infusion (ferric carboxymaltose / ferumoxytol) — has applications well beyond RLS and warrants its own logistics/safety entry.
• Akathisia — drug-induced restlessness that mimics RLS, different fix.

Future-link candidates. Sleep-debt, depression, SSRIs as a class, sleep apnea, ferritin testing — link in once any of those exist.

Ferritin threshold honesty. The 75 / 100 ng/mL pair is the IRLSSG 2018 consensus and the 2025 AASM line, but it is a consensus call, not an RCT-defined cutoff. The article uses the numbers as the operational threshold readers should pressure their doctors with, while the credibility range in research notes that the exact target is unsettled.